Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) announced its earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.
Mosaic ImmunoEngineering Price Performance
Shares of CPMV stock remained flat at $0.06 on Friday. The stock had a trading volume of 817 shares, compared to its average volume of 1,073. The stock has a market cap of $441,762.00, a price-to-earnings ratio of -0.68 and a beta of -0.82. The business has a fifty day moving average of $0.59 and a 200-day moving average of $0.60. Mosaic ImmunoEngineering has a 52 week low of $0.05 and a 52 week high of $1.05.
Mosaic ImmunoEngineering Company Profile
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
Featured Stories
- Five stocks we like better than Mosaic ImmunoEngineering
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
